Oncotarget

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2016; 7(16):22970.

Tudor staphylococcal nuclease drives chemoresistance of non-small cell lung carcinoma cells by regulating S100A11

Anna Zagryazhskaya _, Olga Surova, Nadeem S. Akbar, Giulia Allavena, Katarina Gyuraszova, Irina B. Zborovskaya, Elena M. Tchevkina and Boris Zhivotovsky

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:12156-12173. https://doi.org/10.18632/oncotarget.3495

Metrics: PDF 886 views  |   HTML 1745 views  |   ?  


Abstract

Anna Zagryazhskaya1, Olga Surova1,2, Nadeem S. Akbar1, Giulia Allavena1,3, Katarina Gyuraszova1,4, Irina B. Zborovskaya5,6, Elena M. Tchevkina5,6, Boris Zhivotovsky1,6

1Institute of Environmental Medicine, Division of Toxicology, Stockholm, Sweden

2Ludwig Institute for Cancer Research Ltd, Karolinska Institutet, Stockholm, Sweden

3Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy

4Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Košice, Slovakia

5NN Blokhin Russian Cancer Research Center, Moscow, Russia

6Faculty of Fundamental Medicine, ML Lomonosov State University, Moscow, Russia

Correspondence to:

Boris Zhivotovsky, e-mail: Boris.Zhivotovsky@ki.se

Keywords: tudor staphylococcal nuclease, S100A11, phospholipase A2, non-small cell lung cancer, apoptosis

Received: December 19, 2014     Accepted: March 07, 2015     Published: March 26, 2015

ABSTRACT

Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC), the major lung cancer subtype, is characterized by high resistance to chemotherapy. Here we demonstrate that Tudor staphylococcal nuclease (SND1 or TSN) is overexpressed in NSCLC cell lines and tissues, and is important for maintaining NSCLC chemoresistance. Downregulation of TSN by RNAi in NSCLC cells led to strong potentiation of cell death in response to cisplatin. Silencing of TSN was accompanied by a significant decrease in S100A11 expression at both mRNA and protein level. Downregulation of S100A11 by RNAi resulted in enhanced sensitivity of NSCLC cells to cisplatin, oxaliplatin and 5-fluouracil. AACOCF3, a phospholipase A2 (PLA2) inhibitor, strongly abrogated chemosensitization upon silencing of S100A11 suggesting that PLA2 inhibition by S100A11 governs the chemoresistance of NSCLC. Moreover, silencing of S100A11 stimulated mitochondrial superoxide production, which was decreased by AACOCF3, as well as N-acetyl-L-cysteine, which also mimicked the effect of PLA2 inhibitor on NSCLC chemosensitization upon S100A11 silencing. Thus, we present the novel TSN-S100A11-PLA2 axis regulating superoxide-dependent apoptosis, triggered by platinum-based chemotherapeutic agents in NSCLC that may be targeted by innovative cancer therapies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3495